Das könnte Sie auch interessieren:

Bühne frei - für die Welttourismuskonferenz im Berchtesgadener Land / Tagungsinhalte passen perfekt zur Markenstrategie

Berchtesgaden (ots) - Berchtesgadener Land - Die vierte UNWTO Euro-Asian Mountain Tourism Conference findet ...

TV-Star Isabel Edvardsson: "WW (ehemals Weight Watchers) ist mein Kompass für ein gesundes Leben!"

Düsseldorf (ots) - WW (Weight Watchers) gibt der Profitänzerin (bekannt aus "Let's Dance" und "Das ...

Was die PR-Elite besser macht als der Durchschnitt: Exzellenz in der Unternehmenskommunikation

Hamburg (ots) - Was unterscheidet einen durchschnittlichen von einem herausragenden Kommunikationsprofi? ...

20.12.2018 – 13:50

Merck KGaA

Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

Darmstadt, Germany (ots/PRNewswire)

Not intended for distribution in the USA, Canada or UK

- Agreement enables Merck to maintain an investment in the rapidly 
  advancing oncology field of CAR-T, while focusing its R&D efforts 
- Intrexon to issue Merck $150 million of Intrexon stock and a $25 
  million convertible note; Intrexon to receive a $25 million cash 
  investment  

Merck, a leading science and technology company, today announced that it has evolved its agreement with Intrexon Corporation (NASDAQ: XON) for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. The agreement with Intrexon and its wholly-owned subsidiary, Precigen, Inc., enables Merck to continue to implement its focused R&D strategy, while maintaining an investment in the future potential of next-generation CAR-T development.

Under the terms of the agreement, Merck will assign its exclusive CAR-T development rights to Intrexon. Merck will receive shares of Intrexon common stock valued at $150 million in exchange for assigning Intrexon its CAR-T rights.

"Merck is excited to maintain its interest in the potential of CAR-T technology, which may offer significant future benefits to patients fighting cancer," said Belén Garijo, Member of the Executive Board and CEO Healthcare, Merck. "The agreement is also illustrative of our efforts to enhance our focus on accelerating the delivery of our innovative clinical pipeline to patients."

Merck first entered into a collaboration and license agreement with Intrexon in 2015 to develop and commercialize CAR-T cancer therapies utilizing Intrexon's proprietary RheoSwitch Therapeutic System® and the Sleeping Beauty non-viral gene integration technology. The combination of these platforms enables regulation of gene expression and delivery with a non-viral approach and preclinical data indicate the potential to improve therapeutic safety and facilitate shortened manufacturing to improve time-to-treatment. As of December 31, 2017, these rights were considered intangible assets not yet available for use with a carrying amount of EUR 104 million.

"Merck's leading immuno-oncology research and commitment to developing innovative medicines made them an ideal partner for us in advancing targeted and controllable CAR-T therapies," said Helen Sabzevari, PhD, President of Precigen. "We look forward to continued development of these promising treatments with the goal of delivering more cost-effective, powerful and precise therapies to patients in need."

In addition to receiving $150 million of Intrexon common stock, this agreement also includes a further $25 million investment in Intrexon. In return, Merck will receive a $25 million convertible note, providing the option to receive either Precigen or Intrexon stock. The closing of the transactions contemplated by the agreement is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - Merck is everywhere. In 2017, Merck generated sales of EUR 15.3 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.


(Logo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg )
 

Your Contacts

Media Relations 

friederike.segeberg@merckgroup.com 

Phone: +49-6151-72-6328 
Investor Relations 

investor.relations@merckgroup.com

Phone: +49-6151-72-3321 

Alle Meldungen
Abonnieren Sie alle Meldungen von Merck KGaA
  • Druckversion
  • PDF-Version

Orte in dieser Meldung

Themen in dieser Meldung